Shee K, Jiang A, Varn FS, et al. Cytokine sensitivity screening highlights BMP4 pathway signaling as a therapeutic opportunity in ER breast cancer. FASEB J. 2019;33(2):1644-1657. doi:10.1096/fj.201801241R.
Hamada T, Liu L, Nowak JA, et al. Vitamin D status after colorectal cancer diagnosis and patient survival according to immune response to tumour. Eur J Cancer. 2018;103:98-107. doi:10.1016/j.ejca.2018.07.130.
Bellmunt J, Lalani A-KA, Jacobus S, et al. Everolimus and pazopanib (E/P) benefit genomically selected patients with metastatic urothelial carcinoma. Br J Cancer. 2018;119(6):707-712. doi:10.1038/s41416-018-0261-0.
De Marchi T, Kuhn E, Dekker LJ, et al. Targeted MS Assay Predicting Tamoxifen Resistance in Estrogen-Receptor-Positive Breast Cancer Tissues and Sera. J Proteome Res. 2016;15(4):1230-42. doi:10.1021/acs.jproteome.5b01119.
Duvall JR, Bedard L, Naylor-Olsen AM, et al. Identification of Highly Specific Diversity-Oriented Synthesis-Derived Inhibitors of Clostridium difficile. ACS Infect Dis. 2017;3(5):349-359. doi:10.1021/acsinfecdis.6b00206.
Ritsma L, Dey-Guha I, Talele N, et al. Integrin β1 activation induces an anti-melanoma host response. PLoS One. 2017;12(4):e0175300. doi:10.1371/journal.pone.0175300.
Zhang Y, Ng PK-S, Kucherlapati M, et al. A Pan-Cancer Proteogenomic Atlas of PI3K/AKT/mTOR Pathway Alterations. Cancer Cell. 2017;31(6):820-832.e3. doi:10.1016/j.ccell.2017.04.013.
Robertson G, Kim J, Al-Ahmadie H, et al. Comprehensive Molecular Characterization of Muscle-Invasive Bladder Cancer. Cell. 2017;171(3):540-556.e25. doi:10.1016/j.cell.2017.09.007.
Steinhoff G, Nesteruk J, Wolfien M, et al. Cardiac Function Improvement and Bone Marrow Response -: Outcome Analysis of the Randomized PERFECT Phase III Clinical Trial of Intramyocardial CD133 Application After Myocardial Infarction. EBioMedicine. 2017;22:208-224. doi:10.1016/j.ebiom.2017.07.022.
Shulman DS, Klega K, Imamovic-Tuco A, et al. Detection of circulating tumour DNA is associated with inferior outcomes in Ewing sarcoma and osteosarcoma: a report from the Children's Oncology Group. Br J Cancer. 2018;119(5):615-621. doi:10.1038/s41416-018-0212-9.